Yazar "Basibuyuk, Mustafa" seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Clinical Significance of Incidental Colonic Focal Lesions Detected by FDG PET/CT(Soc Nuclear Medicine Inc, 2015) Elboga, Umut; Sahin, Ertan; Kalender, Ebuzer; Basibuyuk, Mustafa; Demir, Hasan Deniz; Celen, Y. Zeki[Abstract Not Available]Öğe Clinical significance of incidental FDG uptake in the prostate gland detected by PET/CT(E-Century Publishing Corp, 2015) Sahin, Ertan; Elboga, Umut; Kalender, Ebuzer; Basibuyuk, Mustafa; Demir, Hasan Deniz; Celen, Yusuf ZekiThe value of FDG-positron emission tomography/computed tomography (PET/CT) for detecting prostate cancer is unknown. We aimed to investigate the clinical value of incidental prostate FDG uptake on PET/CT scans. We reviewed 6128 male patients who underwent FDG-PET/CT scans and selected cases that reported hypermetabolic lesion in the prostate. The patients who have prior history of prostate carcinoma or prostate surgery were excluded from the study. We have analyzed the correlation between PET/CT findings and serum prostate-specific antigen (PSA) levels, imaging (USG), urological examinations and biopsy. Incidental 18F-FDG uptake of the prostate gland was observed in 79 patients (1.3%). While sixteen of them were excluded due to inadequate clinical data, the remaining 63 patients were included for further analysis. The patients were divided into two groups; 8 patients (12.7%) in the malignant group and 55 patients (87.3%) in the benign group. The SUVmax values were not significantly different between the two groups. In 6 (75%) patients with prostate cancer, FDG uptake was observed focally in the peripheral zone of the prostate glands. There was no significant correlation between the SUVmax and the PSA levels. Incidental 18F-FDG uptake in the prostate gland is a rare condition, but a substantial portion of it is associated with the cancer. Benign and malignant lesions of the prostate gland in FDG-PET/CT imaging could not be reliably distinguished. The peripheral focally FDG uptake of prostate glands should be further examined with the clinical and labaratory evaluations.Öğe Clinical Significance of Incidental FDG Uptake in the Prostate Gland Detected by PET/CT(Soc Nuclear Medicine Inc, 2015) Sahin, Ertan; Elboga, Umut; Kalender, Ebuzer; Basibuyuk, Mustafa; Demir, Hasan Deniz; Celen, Y. Zeki[Abstract Not Available]Öğe Effect of short term thyroxin withdrawal on health related quality of life in differentiated thyroid carcinoma patients(In House Publications, 2015) Elboga, Umut; Elboga, Gülçin; Kalender, Ebuzer; Demir, Hasan Deniz; Sahin, Ertan; Basibuyuk, Mustafa; Aydogan, FusunBackground: We aimed to study the HRQL in patients with differentiated thyroid carcinoma (DTC) during hypothyroidism due to thyroxin withdrawal, which is induced routinely for iodine-131 (I-131) whole body scan and ablative treatment. Methods: Between September 2011 and March 2012, eligible patients with DTC who were referred to our institution for diagnostic or therapeutic radioiodine administration under hypothyroid conditions due to thyroid hormone withdrawal were asked to complete the psychological instruments rating their HRQL and psychological status. HRQL was studied using the Short Form (SF-36), Hospital Anxiety and Depression Scale (HADS), Profile of Mood States (POMS), the total mood disturbance (TMD) score, Beck Depression Inventory (BDI).One hundred and forty three hypothyroid patients with DTC (F=101, M=42, age=58.7 yrs) who were also on low-iodine diet were included in this study. Hypothyroidism was induced by withdrawal of thyroxin replacement in all patients. Results: The results of SF-36 showed that the HRQL was significantly impaired in hypothyroid patients during withdrawal of thyroxin (physical component scale: 44.3 ± 9.5, mental component scale: 40.8 ± 10.2, p ? 0.001). Depression scores were in the normal or non-clinically relevant range: 4.1 ± 3.8 on the HADS-Depression and 8.3 ± 6.6 on the Beck Depression Index. However, the mean score of 28.8 ± 25.2 on the POMS TMD was within normal range. Conclusion: HRQL is impaired in hypothyroid patients with DTC during thyroxine withdrawal before I-131 whole body scan and radioiodine therapy. © 2015 Elboga U, et al.Öğe The Evaluation of Patients with Hyperthyroidism Treated with Radioactive Iodine-131(Derman Medical Publ, 2015) Basibuyuk, Mustafa; Elboga, Umut; Celen, Y. Zeki; Kalender, Ebuzer; Demir, H. Deniz; Sahin, Ertan; Ozkaya, MesutAim: Hyperthyroidism is a condition in which the thyroid gland produces and secretes excessive amounts of the thyroid hormones into circulation. It is one of the common endocrinologic disorders. There are three methods in treatment of hyperthyroidism. These are antithyroid medication, radioactive iodine-131 (RAI) therapy and surgery. In this study, we aimed to evaluate RAI treatment efficacy in patients with hyperthyroidism in the light of laboratory results and clinical pictures. Material and Method: Two hundred and seventy six patients with hyperthyroidism (average age: 50.9 years, age range: 1882 years) who received RAI treatment and then followed up for at least 6 months were included in the study. Patients' medical recordings were analysed retrospectively. Results: Seventy one patients were men (average age: 51.2 years, age range: 18-80 years), the rest were women (average age: 50.7 years, age range: 18-82 years). According to thyroid ultrasound or physical examination findings, 102 patients had diffuse thyroid hyperplasia, the other patients had nondiffuse hyperplasia (nodular or multinodular). RAI was given to the patients once or twice, or three times if necessary. In first RAI treatment, average 13.1 mCi, in second, average 16.6 mCi, in third, average 25 mCi RAI were given orally. Treatment was accepted as successful if the patients had become hypothyroid or euthyroid. Success rate of RAI treatment was 76%. The highest success rate was obtained in patients who have diffuse thyroid hyperplasia. Serious side-effects were not observed in our patients. Discussion: In treatment of hyperthyriodism with RAI in our clinic we observed approximately similar success rates with the reported results in the literature, and also side-effects of RAI treatment were low. We believe that RAI treatment should be first choice for treatment of hyperthyroidism in selected patients, because it is easy to perform and its side- effects are very low.Öğe Regional Distributions of Distant Metastases Detected in Differentiated Thyroid Cancers(Derman Medical Publ, 2015) Kalender, Ebuzer; Elboga, Umut; Aydogan, Fusun; Basibuyuk, Mustafa; Demir, Hasan Deniz; Sahin, Ertan; Celen, Y. ZekiAim: The aim of our multicenter study is to determine retrospectively the regional distributions of distant metastases which are detected in differentiated thyroid cancers (DTC). Material and Method:Thirty-two of 960 patients with distant metastases who were given radioiodine (RAI) treatment in Gaziantep University School of Medicine and Mustafa Kemal University School of Medicine were included to study. Six of patients were male, 26 of them were female. Mean age was 52 15.4. Hystopathological diagnoses were reported as papillary thyroid cancer in 23 patients and folliculary thyroid cancer in 9 patients. The distant metastasis ratio, metastasis regions and distributions were determined. Results: It was observed only lung metastasis in 18 (56.25 b), only bone metastasis in 6 (18.75 To), combination of lung and bone metastases in 3 (9.4 %), other organ metastases accompanying to bone and lung metastases in 5 (9.4 %) (liver, soft tissue, mediastinum) and multipl organ involvoment in 2 (6.2 96) of patients. It was determined single metastasis region in 24 (75 To), 2 metastasis regions in 6 (18.75 glo) and multipl metastasis regions in 2 (6.25 WO of patients. Discussion: Distant metastases are the biggest problem in treatment and follow-up of DTCs. It is very important to diagnosis of metastases and determine the regions of involvoment in these patients.
